The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases
- PMID: 31507535
- PMCID: PMC6718456
- DOI: 10.3389/fendo.2019.00585
The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases
Abstract
Chemokine receptors are members of the G protein-coupled receptor superfamily. These receptors are intimately involved in cell movement, and thus play a critical role in several physiological and pathological situations that require the precise regulation of cell positioning. CXCR4 is one of the most studied chemokine receptors and is involved in many functions beyond leukocyte recruitment. During embryogenesis, it plays essential roles in vascular development, hematopoiesis, cardiogenesis, and nervous system organization. It has been also implicated in tumor progression and autoimmune diseases and, together with CD4, is one of the co-receptors used by the HIV-1 virus to infect immune cells. In contrast to other chemokine receptors that are characterized by ligand promiscuity, CXCR4 has a unique ligand-stromal cell-derived factor-1 (SDF1, CXCL12). However, this ligand also binds ACKR3, an atypical chemokine receptor that modulates CXCR4 functions and is overexpressed in multiple cancer types. The CXCL12/CXCR4/ACKR3 axis constitutes a potential therapeutic target for a wide variety of inflammatory diseases, not only by interfering with cell migration but also by modulating immune responses. Thus far, only one antagonist directed against the ligand-binding site of CXCR4, AMD3100, has demonstrated clinical relevance. Here, we review the role of this ligand and its receptors in different autoimmune diseases.
Keywords: ACKR3; CXCL12 chemokine; CXCR4 = chemokine receptor 4; autoimmunity; chemokines/chemokine receptors; inflammation.
Figures

Similar articles
-
Pathological roles of the homeostatic chemokine CXCL12.Cytokine Growth Factor Rev. 2018 Dec;44:51-68. doi: 10.1016/j.cytogfr.2018.10.004. Epub 2018 Oct 23. Cytokine Growth Factor Rev. 2018. PMID: 30396776 Review.
-
Regulation of the chemokine receptors CXCR4 and ACKR3 by receptor activity-modifying proteins.J Biol Chem. 2025 Jan;301(1):108055. doi: 10.1016/j.jbc.2024.108055. Epub 2024 Dec 9. J Biol Chem. 2025. PMID: 39662834 Free PMC article.
-
The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:541-563. doi: 10.1146/annurev-pharmtox-010919-023340. Epub 2020 Sep 21. Annu Rev Pharmacol Toxicol. 2021. PMID: 32956018
-
ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function.Eur J Clin Invest. 2025 Jan;55(1):e14327. doi: 10.1111/eci.14327. Epub 2024 Oct 7. Eur J Clin Invest. 2025. PMID: 39373210 Free PMC article.
-
The good and bad faces of the CXCR4 chemokine receptor.Int J Biochem Cell Biol. 2018 Feb;95:121-131. doi: 10.1016/j.biocel.2017.12.018. Epub 2017 Dec 27. Int J Biochem Cell Biol. 2018. PMID: 29288743 Review.
Cited by
-
Central human B cell tolerance manifests with a distinctive cell phenotype and is enforced via CXCR4 signaling in hu-mice.Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2021570118. doi: 10.1073/pnas.2021570118. Proc Natl Acad Sci U S A. 2021. PMID: 33850015 Free PMC article.
-
The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?Front Pharmacol. 2024 Jul 12;15:1410104. doi: 10.3389/fphar.2024.1410104. eCollection 2024. Front Pharmacol. 2024. PMID: 39070795 Free PMC article. Review.
-
Modulation of low-dose ozone and LPS exposed acute mouse lung inflammation by IF1 mediated ATP hydrolysis inhibitor, BTB06584.Front Immunol. 2023 Mar 13;14:1126574. doi: 10.3389/fimmu.2023.1126574. eCollection 2023. Front Immunol. 2023. PMID: 36993977 Free PMC article.
-
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies.bioRxiv [Preprint]. 2024 Nov 4:2024.11.04.621790. doi: 10.1101/2024.11.04.621790. bioRxiv. 2024. PMID: 39574661 Free PMC article. Preprint.
-
Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor.Semin Nucl Med. 2024 Jan;54(1):163-170. doi: 10.1053/j.semnuclmed.2023.09.002. Epub 2023 Nov 3. Semin Nucl Med. 2024. PMID: 37923671 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials